Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ferrosoferric oxide
Drug ID BADD_D00886
Description Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [A32478]. It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection [L2181].
Indications and Usage Investigated for use/treatment in anemia, kidney disease, and cardiovascular disorders.
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB06215
KEGG ID Not Available
MeSH ID D052203
PubChem ID 14789
TTD Drug ID D06CTM
NDC Product Code 59338-775; 0781-3154
Synonyms Ferrosoferric Oxide | Oxide, Ferrosoferric | Ferriferrous Oxide | Oxide, Ferriferrous | Magnetite | Feraheme | Ferumoxytol
Chemical Information
Molecular Formula Fe3H2O4
CAS Registry Number 1317-61-9
SMILES O[Fe]=O.O[Fe]=O.[Fe]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Laryngeal oedema22.04.02.001; 10.01.05.003; 23.04.01.005--
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Loss of consciousness17.02.04.004--Not Available
Malignant hypertension24.08.01.002--Not Available
Menopausal symptoms21.02.02.002--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Night sweats08.01.03.031; 23.02.03.006--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oxygen saturation decreased13.02.01.004--Not Available
Pain08.01.08.004--
Paraesthesia17.02.06.005--
Pharyngeal oedema10.01.05.016; 23.04.01.016; 22.04.05.003--Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Pulse absent13.14.04.005--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash generalised23.03.13.002--Not Available
Respiratory arrest22.02.01.009--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Serum ferritin increased13.11.01.026--Not Available
Shock24.06.02.002--Not Available
Skin hyperpigmentation23.05.01.003--
Somnolence19.02.05.003; 17.02.04.006--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages